Exploring Potential: Performing Multi-Criteria Decision Analysis (MCDA) on Orphan Drugs in the Dutch Context

Author(s)

Kok EA, Uyl-De Groot CA
Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands

OBJECTIVES: Orphan drugs can address an unmet medical need but have relatively high prices and uncertainty regarding efficacy due to their small target populations. It is also argued that their value is not adequately captured in the QALY metric used in cost-utility analysis. These factors make it challenging for orphan drugs to meet national cost-effectiveness thresholds, influencing reimbursement decisions and patient access. This study aims to determine if a Multi-Criteria Decision Analysis (MCDA) framework can support orphan drug reimbursement decision-making in the Netherlands.

METHODS: A systematic literature review was conducted from January to April 2024 to identify potentially relevant (orphan) drug value determination criteria. Criteria for a draft MCDA framework were selected based on frequency and relevance claims in grey literature and according to the ISPOR MCDA guidelines. Interviews with 12 Dutch stakeholders (three pediatric clinicians, two hospital pharmacists, two patient representatives, two health economists, and three policymakers) refined the MCDA framework for orphan drugs. Preferences were elicited through prioritization, direct rating, and swing weighting methods and analyzed via ranked summed weighting and direct assignment techniques.

RESULTS: The literature review included 28 publications, describing 32 quantitative and 15 qualitative criteria. The draft MCDA framework incorporated 12 quantitative criteria (four with sub-criteria) and eight qualitative criteria. Interviews resulted in a final MCDA framework with five quantitative criteria: efficacy/effectiveness, disease severity/unmet (medical) needs, therapeutic impact/benefit, safety/tolerability, and quality of evidence, and four contextual criteria: opportunity costs and affordability, population priorities and access, system capacity and appropriate use of the intervention, and expert consensus/clinical practice guidelines. Moreover, dialogue reveals challenges in meeting nonoverlap, preference independence, and operational assumptions.

CONCLUSIONS: This research establishes a pioneering MCDA framework for evaluating first-in-class orphan drugs in the Netherlands to support healthcare decision-making. Even though all participants recognize its potential, there are still some hurdles to overcome.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA268

Topic

Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Novel & Social Elements of Value, Reimbursement & Access Policy, Value Frameworks & Dossier Format

Disease

Drugs, Rare & Orphan Diseases

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×